COMMUNIQUÉS West-GlobeNewswire

Highridge Medical Announces Landmark Positive Policy Decision for The Tether™ Vertebral Body Tethering System
01/04/2026
UnitedHealthcare® policy, exclusively covering The Tether as “medically necessary” for the treatment of pediatric scoliosis, brings coverage to additional patients nationwide WESTMINSTER, Colo., April 01, 2026 (GLOBE [...]
Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026
01/04/2026
WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”), a physician enablement company committed to bringing access to great healthcare to [...]
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
01/04/2026
Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026 SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that [...]
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
01/04/2026
Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc [...]
Vireo Growth Inc. Announces Closing of Acquisition of Eaze Inc.
01/04/2026
Transaction expands Vireo’s operating footprint to 10 states with over 160 dispensaries and approximately 800,000 sq. ft. of cultivation and production Acquisition adds two new markets, California and Florida, and an [...]
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
01/04/2026
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
VivoSim Announces Pricing of up to a $4 Million Public Offering
01/04/2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the [...]
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
01/04/2026
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
Stryker to announce financial results for its first quarter of fiscal year 2026
01/04/2026
Portage, Michigan, April 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2026 on Thursday, April 30, 2026. A press release will be [...]
RemoniHealth Expands Hardware-Free "Vision-as-a-Service" Platform to Cover Over 90% of Chronic Eye Diseases
01/04/2026
Exclusive licensing of new breakthrough, clinic-grade tests to the RemoniHealth platform, solidifies its position as the only integrated RPM and PCM solution for population eye health NEW YORK, April 01, 2026 (GLOBE [...]
electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD
01/04/2026
ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers [...]
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
01/04/2026
Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GIST Bezuclastinib combination [...]
Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week
01/04/2026
Arizona industry event will highlight patient experience, advanced heart failure care, and the real-world impact of life-sustaining therapies TUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE [...]
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
01/04/2026
Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or [...]
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
01/04/2026
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts - - Two [...]
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
01/04/2026
Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage [...]
A Kaleidoscope Inspires the Foundation for Sarcoidosis “See Sarcoidosis” Global Campaign for Sarcoidosis Awareness Month
01/04/2026
CHICAGO, April 01, 2026 (GLOBE NEWSWIRE) -- Often described as a “snowflake disease,” sarcoidosis can affect every patient differently, making it difficult to diagnose, treat, and even recognize. This April, the [...]
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
01/04/2026
GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time modifier gene [...]
Soleo Health Selected as an Authorized Specialty Pharmacy of QIVIGY® For Primary Humoral Immunodeficiency (PI) Treatment
01/04/2026
FRISCO, Texas, April 01, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been named a limited distribution specialty [...]

Pages